Sickle cell disease: Primum non nocere (first do no harm)

Haematologica

Volumn 95, Issue 1, 2010, Pages 4-6

  De Montalembert, Mariane ^a,b,c   Roberts, Irene ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Centre de Référence de la Drépanocytose   (France)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

BLOOD TRANSFUSION; BRAIN BLOOD FLOW; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE INFERTILITY; MORTALITY; NEWBORN SCREENING; QUALITY OF LIFE; RISK FACTOR; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ETHICS, MEDICAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIPPOCRATIC OATH; HUMANS; RISK FACTORS; SURVIVAL RATE;

EID: 73949098991     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020172     Document Type: Editorial

References (20)

1. Vichinsky E, Hurst D, Earles A, Klegman K, Lubin B. Newborn screening for sickle cell disease: effects on mortality. Pediatrics. 1988;81(6):749-55.
2. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007:92(7): 905-12.
3. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
4. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6);1960-4.
5. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140(3):348-54.
6. Hofmann M, de Montalembert M, Beauquier-Maccotta B, de Villartay P, Golse B. Posttraumatic stress disorder in children affected by sickle-cell disease and their parents. Am J Hematol. 2007;82(2): 171-2.
7. Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005;130(3):437-44.
8. Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010;54(1):92-7.
9. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007; 110(7):2749-56.
10. Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP, et al. Center for International Blood and Marrow Transplant Research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479-85.
11. Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL. Bone marrow transplant for sickle cell disease. N Engl J Med. 1991;325(19):1349-53.
12. Brachet C, Heinrichs C, Tenoutasse S, Devalck C, Azzi N, Ferster A. Children with sickle cell disease : growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2007; 29(7):445-50.
13. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2009, doi:10.1016/bbmt.2009.10.005
14. Poirot CJ, Martelli H, Genestie C, Golmard JL, Valteau-Couanet D, Helardot P, et al. Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer. Pediatr Blood Cancer. 2007;49(1):74-8.
15. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-7.
16. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-51.
17. De Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91(1):125-8.
18. Liebelt EL. Reproductive and developmental effect of hydroxyurea. NIH Consens State Sci Statements Development conference: hydroxyurea treatment for sickle cell disease. 2008;25:51-4.
19. Jones KM, Niaz MS, Brooks CM. Adverse effect of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoint. Int J Environ Res Public Health. 2009;6(3):1124-44.
20. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93(7):988-93.